LEAN Project: Weight Loss and Appetite Suppression

The Cooper Institute

Status and phase: Completed; Phase 1

Conditions: Weight Loss

Treatments: Drug: PhosphoLean

Study type: Interventional

Funder types: Other

Identifiers

NCT00153790

CI0151

Details and patient eligibility

About

The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.

Full description

Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.

Sex: Female

Ages: 30 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen

Exclusion criteria

• pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind